HC2 Holdings, Inc. (“HC2”) (NYSE:HCHC), a diversified holding company, announced today that BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc. (“Janssen”).
{iframe}https://globenewswire.com/news-release/2018/05/02/1494775/0/en/HC2-Announces-Pansend-Life-Sciences-Portfolio-Company-BeneVir-Biopharm-to-be-Acquired-by-Janssen-Biotech-Inc-for-up-to-1-04-Billion.html{/iframe}